 "Cipla gains on distribution pact to market paediatric vaccines in Europe")
Cipla has moved higher by 3% to Rs 618 in otherwise weak market on BSE after the pharmaceutical company through its subsidiary Cipla Europe NV, has entered into an agreement to distribute Serum Institute of India Ltd’s (SII) paediatric vaccines in Europe.
As per the agreement, Serum Institute of India, a Poonawalla group company and one of the leading manufacturers of vaccines in India, will develop and manufacture paediatric vaccines, while Cipla will seek European Medicines Agency approval and market the products in Europe, the company said in a press release.
The vaccines will be manufactured in Serum’s production facilities approved by WHO, it added.
The stock opened at Rs 607 and hit a low of Rs 596 in early morning deal on BSE. A combined 1.79 million shares changed hands on the counter till 1200 hours in BSE and NSE.
As per the agreement, Serum Institute of India, a Poonawalla group company and one of the leading manufacturers of vaccines in India, will develop and manufacture paediatric vaccines, while Cipla will seek European Medicines Agency approval and market the products in Europe, the company said in a press release.
The vaccines will be manufactured in Serum’s production facilities approved by WHO, it added.
The stock opened at Rs 607 and hit a low of Rs 596 in early morning deal on BSE. A combined 1.79 million shares changed hands on the counter till 1200 hours in BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%